A Study of KW-6356 in Subjects With Early Parkinson's Disease
Status:
Completed
Trial end date:
2017-12-08
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the effect of KW-6356 on motor symptoms in Parkinson's
disease and the primary endpoint is the change from baseline in the MDS-UPDRS part III score
between KW-6356 and placebo in subjects with early Parkinson's disease in Japan.
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.